Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2019 Feb;33(1):39-52. doi: 10.1016/j.hoc.2018.08.002.

Merkel Cell Carcinoma Review.

Author information

1
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA 02215, USA.
2
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA 02215, USA; Department of Dermatology, Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, 450 Brookline Avenue, Boston, MA 02115, USA. Electronic address: mthakuria1@bwh.harvard.edu.

Abstract

Merkel cell carcinoma is a rare and aggressive cutaneous malignancy of neuroendocrine origin-an often-missed diagnosis due to the wide histopathologic differential diagnosis of malignant small blue cell tumors. The advent of electron microscopy and immunohistochemistry staining for cytokeratin 20, a shared neuroendocrine marker, greatly improved diagnostic accuracy. Over the past decade, staging, treatment, and surveillance of the cancer have progressed at a remarkably rapid pace. Herein, the authors provide an update on the current guidelines around diagnosis and management and review the exciting advancements on the horizon.

KEYWORDS:

Guidelines; Immunotherapy; Merkel cell carcinoma; Merkel cell polyomavirus; Neuroendocrine tumor

PMID:
30497676
DOI:
10.1016/j.hoc.2018.08.002

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center